

R&D Pipeline

● Heme ● Solid tumors ● Non-Oncology

Phase 1

Sonrotoclax	BCL2
● B-cell malignancies	
● AML/MDS	
● MM t(11;14)	
BGB-16673	BTK CDAC
● B-cell malignancies	
BGB-21447	next gen BCL2
● B-cell malignancies	
BGB-A445	OX40
● Solid tumors	
Surzibiclimab	TIM3
● Solid tumors	
BGB-15025 / 26808	HPK1
● 15025- Solid tumors	
● 26808- Solid tumors	
BGB-B167	CEA x 41BB
● CRC, NSCLC, GC	
BGB-30813	DGKζ
● Solid tumors	
BGB-A3055	CCR8
● Solid tumors	
BGB-24714	SMAC mimetic
● Solid tumors	
BGB-10188	PI3Kδ
● Solid tumors	
Zanidatamab¹	HER2 BsAb
● 1L mBC/GC	
Xaluritamig²	STEAP1 x CD3
● mCRPC (initiation activities)	

Phase 2

Zanubrutinib	BTK
● B-cell lymphoma	
● CD79B R/R DLBCL	
● Lupus nephritis	
Sonrotoclax	BCL2
● R/R MCL	
● R/R CLL	
● R/R WM	
Ociperlimab	TIGIT
● 1L NSCLC	
LBL-007³	LAG3
● MSS-CRC	
● 1L ESCC (initiation activities)	
BGB-A445	OX40
● Melanoma, RCC, UC	
Umbrella Study	Multiple
● 1L NSCLC	
● 2L+ NSCLC	
● Neoadj NSCLC	
● 1L HNSCC	
Zanidatamab¹	HER2 BsAb
● HER2+ 2L BTC	

Phase 3

Zanubrutinib	BTK
● TN MCL	
● R/R MZL, R/R FL	
● pMN	
Sonrotoclax	BCL2
● TN CLL (initiation activities)	
Tislelizumab	PD1
● Neo/adj NSCLC*	
● 1L UBC	
● LA ESCC	
● R/R cHL	
Pamiparib	PARP
● 2L MTx gBRCAm PSOC	
Ociperlimab	TIGIT
● 1L NSCLC PDL1-high	
Zanidatamab¹	HER2 BsAb
● 1L HER2+ GEA	
Tarlatamab²	DLL x CD3
● 2L SCLC	

Registration

Zanubrutinib	BTK
● TN CLL/SLL (JP)	
● R/R CLL/SLL (US - PFS, JP)	
● R/R FL (US, EU, CN)	
● TN WM (JP)	
Tislelizumab	PD1
● 1L NSCLC (EU)	
● 2/3L NSCLC (EU)	
● 1L Sq, NSCLC (EU)	
● 1L ES-SCLC (CN)	
● 1L GC/GEJC (CN)	
● 1L HCC (CN)	
● 1L ESCC (US)	
● 2L ESCC (US)	

Approved

Zanubrutinib	BTK
● TN CLL/SLL (US, EU, CN, Others)	
● R/R CLL/SLL (US, EU, Others)	
● R/R CLL (CN)	
● R/R MCL (US, CN, Others)	
● R/R MZL (US, EU, Others)	
● TN WM (US, EU, CN, Others)	
Tislelizumab	PD1
● 1L Non-sq, NSCLC (CN)	
● 1L Sq, NSCLC (CN)	
● 2/3L NSCLC (CN)	
● 1L GC (CN)	
● 2/3L HCC (CN)	
● 1L ESCC (CN)	
● 2L ESCC (EU, CN)	
● 2L UBC (CN)	
● 1L NPC (CN)	
● 2L MSI-H/dMMR (CN)	
● R/R cHL (CN)	
Pamiparib	PARP
● 2L gBRCAm OC (CN)	

Registration includes select accepted submissions

* Primary endpoint met

CN = China

1. Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights

2. Amgen collaboration, BeiGene has China commercial rights

3. Leads Biolabs collaboration, BeiGene has ex-China commercial rights